Episode 248: The effect of NSAIDs on fracture healing – much ado about nothing?

In episode 248, Mike and James and Mike tackle another Tools For Practice and discuss the myth about NSAIDs and delayed fracture healing and review all the evidence. At the end we join everything all together and NSAIDs didn’t in anyway prevent that.

Show notes

 1) Tools For Practice Read more »

Episode 247: How the new anticoagulants compare to warfarin in DVTs and PEs

In episode 247, Mike and James and Mike look at the evidence for the new anticoagulants compared to warfarin in the treatment of DVTs and PEs. At the end we realise the decision between these agents is a personal one guided by the best available evidence, which hopefully we have done an OK job in providing.

Show notes

 1) Tools For Practice Read more »

Episode 246: Clearing up the confusion around statin-induced cognitive impairment

In episode 246, Mike and James go over all the evidence that has looked at the issue of statins and cognitive impairment. Overall the evidence is not confusing and it indicates that statins do not prevent, treat, or cause cognitive impairment or dementia. Still confused?

Show notes

1) Tools For Practice Read more »

Episode 245: Three studies you need to know about – so get a PREMIUM membership!

In episode 245, Mike and James PREMIUM the listeners with talk about three new studies. Aleglitazar a new drug that was supposed to help people with type 2 diabetes, how best to use delayed antibiotic prescribing and a trial that answers the question about population screening for high cardiovascular risk patients.

Show notes

1) AleCardio - aleglitazar Read more »

Episode 244: Industry and us - PART IV

In episode 244, Mike and James continue to delve into issues around industry and discuss the costs of research, patent protection, and policies on industry relations. At the end we come to the conclusion that the phrase industry and us includes 2 people so everybody plays a role in the process.

Show notes

1) Industry and us Read more »

Episode 243: Industry and us - PART III

In episode 243, Mike and James continue to delve into issues around industry and we now focus on how study design, selection of comparators and selective publication can impact the “truth”.

Show notes

 1) Industry and us  Read more »

Episode 242: Industry and us - PART II

In episode 242, Mike and James continue to delve into the impact industry marketing has on how and why we prescribe. We get to the evidence around many of the influences and at the end we realize we are all influenced by many things and we are all biased – so deal with it by being aware of the influence.

Show notes

1) Industry and us  Read more »

Episode 241: Industry and us

In episode 241, Mike and James decide to delve into the impact industry marketing has on how and why we prescribe. We start off by discussing the theoretical issues surrounding the marketing of medications and briefly touch on the ethical dilemmas. Read more »